Stanford tests bold move: stop rejection drug early after transplant
NCT ID NCT07302776
Summary
This study aims to see if it's safe and possible to stop a key anti-rejection medication (tacrolimus) much earlier than usual after a bone marrow transplant. It will involve 50 adults with various blood cancers who receive a transplant from a matched donor. The goal is to reduce long-term medication side effects while still preventing the body from rejecting the new cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.